 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DOXEPIN HCL increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"DOXEPIN HCL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDOXEPIN HCL[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDOXEPIN HCL[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"DOXEPIN HCL"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"DOXEPIN HCL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: DOXEPIN HCL: description: Doxepin hydrochloride, USP is one of a class of psychotherapeutic agents known as dibenzoxepin tricyclic compounds. The molecular formula of the compound is [0m
[31mC19H21NOâ€¢HCl having a molecular weight of [0m[1;31m316[0m[31m. It is a white or almost white crystalline powder freely soluble in water, alcohols and methylene chloride. It may be represented by the following [0m
[31mstructural formula. [0m[31m Chemically, doxepin hydrochloride, USP is a dibenzoxepin derivative and is the first of a family of tricyclic psychotherapeutic agents. Specifically, it is an isomeric mixture [0m
[31mo[0m[1;31mf:1[0m[31m-Propanamine, [0m[1;31m3[0m[31m-dibenz[0m[31moxepin-[0m[1;31m11[0m[1;31m([0m[31m6H[0m[1;31m)[0m[31mylidene-N,N-dimethyl-, hydrochloride. DOXEPIN HCL: description: Each [0m[1;31m10[0m[31m mg, [0m[1;31m25[0m[31m mg, [0m[1;31m50[0m[31m mg, [0m[1;31m75[0m[31m mg and [0m[1;31m100[0m[31m mg doxepin capsule, USP for oral administration contains [0m
[31mdoxepin hydrochloride, USP equivalent to [0m[1;31m10[0m[31m mg, [0m[1;31m25[0m[31m mg, [0m[1;31m50[0m[31m mg, [0m[1;31m75[0m[31m mg and [0m[1;31m100[0m[31m mg doxepin, respectively and the following inactive ingredients: microcrystalline cellulose, pregelatinized starch, sodium [0m
[31mlauryl sulfate and magnesium stearate The hard gelatin capsule shell contain titanium dioxide, gelatin, sodium lauryl sulfate, FD & C Yellow [0m[1;31m6[0m[31m, D & C Yellow [0m[1;31m10[0m[31m, and FD & C Green [0m[1;31m3[0m[31m. The imprinting ink [0m
[31mcontains shellac, propylene glycol, black iron oxide and potassium hydroxide.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: spl_product_data_elements: Doxepin HCL Doxepin HCL MAGNESIUM STEARATE SHELLAC DOXEPIN HYDROCHLORIDE DOXEPIN MICROCRYSTALLINE CELLULOSE GELATIN, UNSPECIFIED D&C YELLOW NO. [0m[1;31m10[0m[31m [0m
[31mSTARCH, CORN SODIUM LAURYL SULFATE POTASSIUM HYDROXIDE FD&C YELLOW NO. DOXEPIN HCL: spl_product_data_elements: [0m[1;31m6[0m[31m PROPYLENE GLYCOL FERROSOFERRIC OXIDE TITANIUM DIOXIDE Ivory opaque ap;DXP25 white [0m
[31mopaque         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: indications_and_usage: Doxepin Hydrochloride Capsules, USP are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety[0m
[31massociated with alcoholism [0m[1;31m([0m[31mnot to be taken concomitantly with alcohol[0m[1;31m)[0m[31m. Depression and/or anxiety associated with organic disease [0m[1;31m([0m[31mthe possibility of drug interaction should be considered if the [0m
[31mpatient is receiving other drugs concomitantly[0m[1;31m)[0m[31m. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of [0m
[31mpsychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, [0m
[31mapprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules is safe and well tolerated even in the elderly patient. DOXEPIN HCL: indications_and_usage: Owing to lack of [0m
[31mclinical experience in the pediatric population, doxepin is not recommended for use in children under [0m[1;31m12[0m[31m years of age.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: clinical_pharmacology: The mechanism of action of doxepin is not definitely known. It is not a central nervous system stimulant nor a monoamine oxidase inhibitor. The current [0m
[31mhypothesis is that the clinical effects are due, at least in part, to influences on the adrenergic activity at the synapses so that deactivation of norepinephrine by reuptake into the nerve terminals [0m
[31mis prevented. Animal studies suggest that doxepin HCl does not appreciably antagonize the antihypertensive action of guanethidine. In animal studies anticholinergic, antiserotonin and antihistamine [0m
[31meffects on smooth muscle have been demonstrated. At higher than usual clinical doses, norepinephrine response was potentiated in animals. This effect was not demonstrated in humans. DOXEPIN HCL: [0m
[31mclinical_pharmacology: At clinical dosages up to [0m[1;31m150[0m[31m mg per day, doxepin can be given to man concomitantly with guanethidine and related compounds without blocking the antihypertensive effect. At [0m
[31mdosages above [0m[1;31m150[0m[31m mg per day blocking of the antihypertensive effect of these compounds has been reported. Doxepin is virtually devoid of euphoria as a side effect. Characteristic of this type of [0m
[31mcompound, doxepin has not been demonstrated to produce the physical tolerance or psychological dependence associated with addictive compounds.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: contraindications: Doxepin is contraindicated in individuals who have shown hypersensitivity to the drug. Possibility of cross sensitivity with other dibenzoxepines should be [0m
[31mkept in mind. Doxepin is contraindicated in patients with glaucoma or a tendency to urinary retention. These disorders should be ruled out, particularly in older patients.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Doxepin hydrochloride [0m[1;32m([0m[32mHCL[0m[1;32m)[0m[32m is a dibenzoxepin tricyclic compound used as a psychotherapeutic agent. It is available in various dosages for oral administration, including [0m[1;32m10[0m[32m mg, [0m[1;32m25[0m[32m mg, [0m[1;32m50[0m[32m mg, [0m
[1;32m75[0m[32m mg, and [0m[1;32m100[0m[32m mg capsules. The medication is indicated for the treatment of psychoneurotic patients with depression and/or anxiety, depression and/or anxiety associated with alcoholism [0m[1;32m([0m[32mnot to be [0m
[32mtaken with alcohol[0m[1;32m)[0m[32m, and depression and/or anxiety associated with organic disease. It is also used for psychotic depressive disorders with associated anxiety, including involutional depression and [0m
[32mmanic-depressive disorders. Doxepin HCL is considered safe and well-tolerated, even in elderly patients, but is not recommended for children under [0m[1;32m12[0m[32m years of age due to a lack of clinical experience.[0m
[32mThe mechanism of action is believed to be related to preventing the reuptake of norepinephrine into nerve terminals, thus affecting adrenergic activity at synapses. Doxepin HCL is contraindicated in [0m
[32mindividuals with hypersensitivity to the drug, those with glaucoma, or a tendency to urinary retention.[0m

[32mSOURCE: DOXEPIN HCL label[0m
[32mEXTRACT_START_END: Doxepin hydrochloride, USP is [0m[32m...[0m[32m associated with organic disease.[0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Doxepin hydrochloride [0m[1;34m([0m[34mHCL[0m[1;34m)[0m[34m is a dibenzoxepin tricyclic compound[0m
[34mused as a psychotherapeutic agent. It is available in various dosages for oral administration, including [0m[1;34m10[0m[34m mg, [0m[1;34m25[0m[34m mg, [0m[1;34m50[0m[34m mg, [0m[1;34m75[0m[34m mg, and [0m[1;34m100[0m[34m mg capsules. The medication is indicated for the treatment [0m
[34mof psychoneurotic patients with depression and/or anxiety, depression and/or anxiety associated with alcoholism [0m[1;34m([0m[34mnot to be taken with alcohol[0m[1;34m)[0m[34m, and depression and/or anxiety associated with organic [0m
[34mdisease. It is also used for psychotic depressive disorders with associated anxiety, including involutional depression and manic-depressive disorders. Doxepin HCL is considered safe and [0m
[34mwell-tolerated, even in elderly patients, but is not recommended for children under [0m[1;34m12[0m[34m years of age due to a lack of clinical experience. The mechanism of action is believed to be related to [0m
[34mpreventing the reuptake of norepinephrine into nerve terminals, thus affecting adrenergic activity at synapses. Doxepin HCL is contraindicated in individuals with hypersensitivity to the drug, those [0m
[34mwith glaucoma, or a tendency to urinary retention.[0m

[34mSOURCE: DOXEPIN HCL label[0m
[34mEXTRACT_START_END: Doxepin hydrochloride, USP is [0m[34m...[0m[34m associated with organic disease.[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DOXEPIN HCL increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DOXEPIN HCL increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DOXEPIN HCL increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DOXEPIN HCL increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"DOXEPIN HCL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does DOXEPIN HCL increase or decrease the risk of [0m
[31mrenal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDAHandler has indicated that the FDA label for DOXEPIN HCL does not [0m
[32mspecify information regarding the drug's effect on the risk of renal failure. This suggests that there may not be a well-established or recognized effect of DOXEPIN HCL on renal failure risk, or that [0m
[32mit has not been sufficiently studied or reported to warrant inclusion in the label.[0m

[32mGiven this lack of information from the FDA label, I cannot provide a definitive answer to whether DOXEPIN HCL increases or decreases the risk of renal failure.[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DOXEPIN HCL increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether DOXEPIN HCL increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for DOXEPIN HCL does not specify information regarding its effect on the risk of renal failure."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DOXEPIN HCL increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether DOXEPIN HCL increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for DOXEPIN HCL does not specify information regarding its effect on the risk of renal failure."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DOXEPIN HCL increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether DOXEPIN HCL increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded with DO-NOT-KNOW, indicating that the FDA label for DOXEPIN HCL does not specify information regarding its effect on the risk of renal failure.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDAHandler has indicated that the FDA label for DOXEPIN HCL does not contain information regarding its effect on the risk of renal failure. Therefore, I cannot provide a definitive answer to [0m
[32mwhether DOXEPIN HCL increases or decreases the risk of renal failure. The absence of this information in the FDA label suggests that there may not be a well-established or recognized effect, or that [0m
[32mit has not been sufficiently studied or reported to warrant inclusion in the label.[0m
